OXPZero™️ Drug Formulation Platform Technology
Layered Double Hydroxide (LDH) Platform Technology
Oxford PharmaScience’s proprietary LDH technology creates novel salt forms of established analgesic APIs with enhanced performance characteristics.
How It Works
Layered Double Hydroxides host anionic drug molecules between positively charged metal-hydroxide layers, providing:
• Modified release kinetics
• Intrinsic taste-masking
• Improved stability
• Compatibility with multiple dosage formats
Platform Benefits
Faster Absorption (Oxprofen) – In a dedicated pharmacokinetic study (OAT-01), the LDH form of ibuprofen (Oxprofen™) achieved a Tmax of ≈ 30 minutes – 25–35 % faster than ibuprofen lysine (Tmax ≈ 40–45 min) in a direct head-to-head study, while remaining bioequivalent for AUC and Cmax.
Superior Taste-Masking – The LDH structure eliminates bitterness and throat burn, enabling palatable formats such as ODTs, granules, drinks and chewables.
Designed for Gastric Comfort – Early endoscopy data indicate reduced gastric-irritation potential compared to standard ibuprofen formulations.
Flexible Formulation Options – Adaptable to OTC pain products, acute-care prescription use, paediatric formulations and specialty applications.
Regulatory Pathway
LDH salts such as Oxprofen can be registered either via the 505(b)(2) (US) or 10(3) hybrid (EU) routes — or directly as OTC formulations — providing maximum flexibility with no new efficacy studies required.
Platform Extensions
The LDH platform extends beyond ibuprofen to other anionic NSAIDs such as naproxen, where early work shows faster absorption and potential for improved gastric comfort at higher Rx doses. This supports the development of a complete family of fast-acting, consumer-friendly analgesics under a single, IP-protected technology.
